Honda K, et al. - Researchers evaluated apolipoprotein A2 (ApoA2) isoform (“ApoA2-ATQ/AT”), alone and in combination with carbohydrate antigen 19-9 (CA19-9), as an early detection biomarker for pancreatic cancer. Using plasma samples collected up to 60 months prior to diagnosis, they performed ELISA measurements of CA19-9 and ApoA2-ATQ/AT in 156 patients with pancreatic cancer and 217 matched controls within the European EPIC cohort. Detection of pancreatic cancer up to 18 months prior to diagnosis under usual care may be improved by the combination of CA19-9 and ApoA2-ATQ/AT vs CA19-9 alone. They noted this combination may provide a useful first measure for pancreatic cancer detection before imaging.